Blood Reviews
Volume 23, Issue 5 , Pages 225-229 , September 2009

Basic mechanisms and pathogenesis of venous thrombosis

  • Charles T. Esmon

      Affiliations

    • Corresponding Author InformationAddress: Cardiovascular Biology Research Program, Oklahoma Medical Research Foundation, Howard Hughes Medical Institute, 825 NE 13th Street, Oklahoma City, OK 73104, United States. Tel.: +1 405 271 6474; fax: +1 405 271 2872.

References 

  1. Aird WC. Vascular bed-specific thrombosis. J Thromb Haemost. 2007;5:283–291
  2. Lane DA, Grant PJ. Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease. Blood. 2000;95:1517–1532
  3. Giles AR, Mann KG, Nesheim ME. A combination of factor Xa and phosphatidylcholine–phosphatidylserine vesicles bypasses factor VIII in vivo. Br J Haematol. 1988;69:491–497
  4. Taylor FB, He SE, Chang ACK, et al. Infusion of phospholipid vesicles amplifies the local thrombotic response to TNF and anti-protein C into a consumptive response. Thromb Haemost. 1996;75:578–584
  5. Sevitt S. The structure and growth of valve-pocket thrombi in femoral veins. J Clin Pathol. 1974;27:517–528
  6. Friedman SA. Peripheral venous disease. In:  Beers MH,  Berkow R editor. The merck manual of geriatrics. 3rd ed.. Whitehouse Station, NJ: Merck Research Laboratories; 2000;p. 923–932
  7. Paterson JC, McLachlin J. Precipitating factors in venous thrombosis. Surg Gynecol Obstet. 1954;98:96–102
  8. Gottlob M, May R. Part III. Pathologic venous valves. In:  Gottlob R,  May R editor. Venous valves: morphology, function, radiology, surgery. New York, NY: Springer-Verlag; 1986;p. 82–92
  9. Lund FL, Diener L, Ericsson JLE. Postmortem intraosseous phlebography as an aid in studies of venous thromboembolism: with application on a geriatric clientele. Angiology. 1969;20:155–176
  10. McLachlin AD, McLachlin JA, Jory TA, Rawling EG. Venous stasis in the lower extremities. Ann Surg. 1960;152:678–683
  11. Hamer JD, Malone PC, Silver IA. The PO2 in venous valve pockets: its possible bearing on thrombogenesis. Br J Surg. 1981;68:166–170
  12. Brooks EG, Trotman W, Wadsworth MP, et al. Valves of the deep venous system: The overlooked risk factor. Blood 2009; in press, doi:10.1182/blood-2009-03-209981.
  13. Esmon CT. Inflammation and the activated protein C anticoagulant pathway. Semin Thromb Hemost. 2006;32(Suppl. 1):49–60
  14. Dufourcq P, Seigneur M, Pruvost A, et al. Membrane thrombomodulin levels are decreased during hypoxia and restored by cAMP and IBMX. Thromb Res. 1994;77:305–310
  15. Ogawa S, Gerlach H, Esposito C, Pasagian-Macaulay A, Brett J, Stern D. Hypoxia modulates the barrier and coagulant function of cultured bovine endothelium: increased monolayer permeability and induction of procoagulant properties. J Clin Invest. 1990;85:1090–1098
  16. Shreeniwas R, Ogawa S, Cozzolino F, et al. Macrovascular and microvascular endothelium during long-term hypoxia: Alterations in cell growth, monolayer permeability, and cell surface coagulant properties. J Cell Physiol. 1991;146:8–17
  17. Yan S-F, Mackman N, Kisiel W, Stern DM, Pinsky DJ. Hypoxia/hypoxemia-induced activation of the procoagulant pathways and the pathogenesis of ischemia-associated thrombosis. Arterioscler Thromb Vasc Biol. 1999;19:2029–2035
  18. Closse C, Seigneur M, Renard M, et al. Influence of hypoxia and hypoxia-reoxygenation on endothelial P-selectin expression. Thromb Res. 1996;85:159–164
  19. Myers DD, Hawley AE, Farris DM, et al. P-selectin and leukocyte microparticles are associated with venous thrombogenesis. J Vasc Surg. 2003;38:1075–1089
  20. Falati S, Liu Q, Gross P, et al. Accumulation of tissue factor into developing thrombi in vivo is dependent upon microparticle P-selectin glycoprotein 1 and platelet P-selectin. J Exp Med. 2003;197:1585–1598
  21. Giesen PLA, Rauch U, Bohrmann B, et al. Blood-borne tissue factor: another view of thrombosis. Proc Natl Acad Sci (USA). 1999;96:2311–2315
  22. Drake TA, Morrissey JH, Edgington TS. Selective cellular expression of tissue factor in human tissues: Implications for disorders of hemostasis and thrombosis. Am J Pathol. 1989;134:1087–1097
  23. Li R, Riordan F, Hu G-F. Nuclear translocation of human angiogenin in cultured human umbilical artery endothelial cells is microtubule and lysosome independent. Biochem Biophys Res Commun. 1997;238:305–312
  24. Myers DD, Rectenwald JE, Bedard PW, et al. Decreased venous thrombosis with an oral inhibitor of P selectin. J Vasc Surg. 2005;42:329–336
  25. Wakefield TW, Strieter RM, Schaub R, et al. Venous thrombosis prophylaxis by inflammatory inhibition without anticoagulation therapy. J Vasc Surg. 2000;31:309–324
  26. Yamauchi T, Umeda F, Inoguchi T, Nawata H. Antithrombin III stimulates prostacyclin production by cultured aortic endothelial cells. Biochem Biophys Res Commun. 1989;163:1404–1411
  27. Paterson JC, McLachlin J. Precipitating factors in venous thrombosis. Surg Gynecol Obstet. 1954;98:96–102
  28. Day SM, Reeve JL, Pedersen B, et al. Macrovascular thrombosis is driven by tissue factor derived primarily from the blood vessel wall. Blood. 2005;105:192–198
  29. Esmon CT. Blood coagulation. In: 6th ed..  Nathan DG,  Orkin SH,  Ginsburg D,  Look AT editor. Nathan and Oski’s hematology of infancy and childhood. vol. 2:Philadelphia, PA: W.B. Saunders Company; 2003;p. 1475–1496
  30. Busch C, Cancilla P, DeBault L, Goldsmith J, Owen W. Use of endothelium cultured on microcarriers as a model for the microcirculation. Lab Invest. 1982;47:498–504
  31. Esmon CT, Owen WG. Identification of an endothelial cell cofactor for thrombin-catalyzed activation of protein C. Proc Natl Acad Sci (USA). 1981;78:2249–2252
  32. Esmon CT. The roles of protein C and thrombomodulin in the regulation of blood coagulation. J Biol Chem. 1989;264:4743–4746
  33. Lane DA, Mannucci PM, Bauer KA, et al. Inherited thrombophilia: Part 1. Thromb Haemost. 1996;76:651–662
  34. Lane DA, Mannucci PM, Bauer KA, et al. Inherited thrombophilia: Part 2. Thromb Haemost. 1996;76:824–834
  35. Bertina RM. Elevated clotting factor levels and venous thrombosis. Pathophysiol Haemost Thromb. 2004;33:399–400
  36. Smirnov MD, Safa O, Esmon NL, Esmon CT. Inhibition of activated protein C anticoagulant activity by prothrombin. Blood. 1999;94:3839–3846
  37. Rosendaal FR. Venous thrombosis: a multicausal disease. Lancet. 2009;353:1167–1173
  38. Esmon CT, Schwarz HP. An update on clinical and basic aspects of the protein C anticoagulant pathway. Trends Cardiovasc Med. 1995;5:141–148
  39. Schwarz HP, Fischer M, Hopmeier P, Batard MA, Griffin JH. Plasma protein S deficiency in familial thrombotic disease. Blood. 1984;64:1297–1300
  40. Kunz G, Ireland HA, Stubbs PJ, Kahan M, Coulton GC, Lane DA. Identification and characterization of a thrombomodulin gene mutation coding for an elongated protein with reduced expression in a kindred with myocardial infarction. Blood. 2000;95:569–576
  41. Biguzzi E, Merati G, Liaw PCY, et al. A 23bp insertion in the endothelial protein C receptor (EPCR) gene impairs EPCR function. Thromb Haemost. 2001;86:945–948
  42. Faust SN, Levin M, Harrison OB, et al. Dysfunction of endothelial protein C activation in severe meningococcal sepsis. New Engl J Med. 2001;345:408–416
  43. Laszik ZG, Zhou XJ, Ferrell GL, Silva FG, Esmon CT. Down-regulation of endothelial expression of endothelial cell protein C receptor and thrombomodulin in coronary atherosclerosis. Am J Pathol. 2001;159:797–802
  44. Mertens G, Cassiman J-J, Van den Berghe H, Vermylen J, David G. Cell surface heparin sulfate proteoglycans from human vascular endothelial cells. J Biol Chem. 1992;267:20435–20443
  45. Lowe GDO, Rumley A, Woodward M, et al. Epidemiology of coagulation factors, inhibitors and activation markers: the third glasgow MONICA survey I. Illustrative reference ranges by age, sex and hormone use. Br J Haematol. 1997;97:775–784
  46. Li C, Ford ES, McGuire LC, Mokdad AH. Increasing trends in waist circumference and abdominal obesity among U.S. adults. Obesity (Silver Spring). 2007;15:216–224
  47. Silverstein RL, Bauer KA, Cushman M, Esmon CT, Ershler WB, Tracy RP. Venous thrombosis in the elderly: more questions than anwers. Blood. 2007;110:3097–3101
  48. van Stralen KJ, Doggen CJM, Lumley T, et al. The relationship between exercise and risk of venous thrombosis in elderly people. JAGS. 2008;56:517–522
  49. Torn M, Bollen WLEM, van der Meer FJM, van der Wall EE, Rosendaal FR. Risks of oral anticoagulant therapy with increasing age. Arch Intern Med. 2005;165:1527–1532
  50. Rosendaal FR, Van Hylckama Vlieg A, Doggen CJM. Venous thrombosis in the elderly. J Thromb Haemost. 2007;5(Suppl. 1):310–317
  51. Tsai AW, Cushman M, Rosamond WD, et al. Coagulation factors, inflammation markers, and venous thromboembolism: the longitudinal investigation of thromboembolism etiology (LITE). Am J Med. 2002;113:636–642
  52. Smeeth L, Cook C, Thomas S, Hall AJ, Hubbard R, Vallance P. Risk of deep vein thrombosis and pulmonary embolism after acute infection in a community setting. Lancet. 2006;367:1075–1079
  53. Bovill EG, Bauer KA, Dickerman JD, Callas P, West B. The clinical spectrum of heterozygous protein C deficiency in a large New England kindred. Blood. 1989;73:712–717
  54. Abdollahi M, Cushman M, Rosendaal FR. Obesity: risk of venous thrombosis and the interaction with coagulation factor levels and oral contraceptive use. Thromb Haemost. 2003;89:493–498
  55. Sidney S, Petitti DB, Soff GA, Cundiff DL, Tolan KK, Quesenberry CP. Venous thromboembolic disease in users of low-estrogen combined estrogen-progestin oral contraceptives. Contraception. 2004;70:3–10
  56. Lim W, Eikelboom JW, Ginsberg JS. Inherited thrombophilia and pregnancy associated venous thromboembolism. BMJ. 2007;334:1318–1321
  57. Bick RL. Cancer-associated thrombosis. New Engl J Med. 2003;349:109–111
  58. Kakkar AK, Levine M, Pinedo HM, Wolff R, Wong J. Venous thrombosis in cancer patients: insights from the FRONTLINE survey. Oncologist. 2003;8:381–388
  59. Horton J. Venous thrombotic events in cancer: the bottom line. Cancer Control. 2005;12(Suppl. 1):31–37
  60. Piccioli A, Prandoni P, Ewenstein BM, Goldhaber SZ. Cancer and venous thromboembolism. Am Heart J. 1996;132:850–855
  61. López JA, Kearon C, Lee AYY. Deep venous thrombosis. In: Hematology American Society of Hematology Education Program Book. Wash., DC: American Society of Hematology; 2004. p. 439–56.
  62. Dvorak HF, Quay SC, Orenstein NS, et al. Tumor shedding and coagulation. Science. 1981;212:923–924
  63. Rao LV. Tissue factor as a tumor procoagulant. Cancer Metastasis Rev. 1992;11:249–266
  64. de Groot PG, Derksen RHWM. Pathophysiology of the antiphospholipid syndrome. J Thromb Haemost. 2005;3:1854–1860
  65. Del Papa N, Sala GA, Buccellati C, et al. Endothelial cells as target for antiphospholipid antibodies: Human polyclonal and monoclonal anti-β2-glycoprotein I antibodies react in vitro with endothelial cells through adherent β2-glycoprotein I and induce endothelial activation. Arthritis Rheum. 1997;40:551–561
  66. Holers VM, Girardi G, Mo L, et al. Complement C3 activation is required for antiphospholipid antibody-induced fetal loss. J Exp Med. 2002;195:211–220
  67. Atsumi T, Khamashta MA, Amengual O, et al. Binding of anticardiolipin antibodies to protein C via β2-glycoprotein I (β2-GPI): a possible mechanism in the inhibitory effect of antiphospholipid antibodies on the protein C system. Clin Exp Immunol. 1998;112:325–333
  68. Galli M, Ruggeri L, Barbui T. Differential effects of anti-β-glycoprotein I and antiprothrombin antibodies on the anticoagulant activity of activated protein C. Blood. 1998;91:1999–2004
  69. Smirnov MD, Triplett DT, Comp PC, Esmon NL, Esmon CT. On the role of phosphatidylethanolamine in the inhibition of activated protein C activity by antiphospholipid antibodies. J Clin Invest. 1995;95:309–316
  70. Esmon NL, Safa O, Smirnov MD, Esmon CT. Antiphospholipid antibodies and the protein C pathway. J Autoimmunity. 2000;15:221–225
  71. Carson CW, Comp PC, Esmon NL, Rezaie AR, Esmon CT. Antibodies to thrombomodulin are found in patients with lupus anticoagulant and unexplained thrombosis. J Rheumatol. 2000;27:384–390
  72. Weitz JI, Hirsh J. Overview of new anticoagulant drugs. In:  Sasahara AA,  Loscalzo J editor. New therapeutic agents in thrombosis and thrombolysis. 2nd ed.. New York, NY: Marcel Dekker, Inc.; 2003;p. 61–74

PII: S0268-960X(09)00040-X

doi: 10.1016/j.blre.2009.07.002

Blood Reviews
Volume 23, Issue 5 , Pages 225-229 , September 2009

Article Tools

* Image Usage & Resolution